Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Efficacy and Safety of Cholinesterase Inhibitors and Memantine in Cognitive Impairment in Parkinsons Disease, Parkinsons Disease Dementia, and Dementia with Lewy Bodies: Systematic Review with Meta-Analysis and Trial Sequential Analysis
JNNP 86:135-143, Wang, H.F.,et al, 2015
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005
Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005
Size of the Treatment Effect on Cognition of Cholinesterase Inhibition in Alzheimer's Disease
JNNP 75:677-685, Rockwood,K., 2004
Long-term Donepezil Treatment in 565 Patients with Alzheimer's Disease (AD2000): Randomised Double-Blind Trial
Lancet 363:2105-2115,2100, AD2000 Collaborative Group, 2004
Rivastigmine for Dementia Associated with Parkinson's Disease
NEJM 351:2509-2518,2547, Emre,M.,et al, 2004
Acetylcholinesterase Inhibitors for Vascular Dementia and Alzheimer's Disease Combined With Cerebrovascular Disease
Stroke 34:584-586, Bowler,J.V., 2003
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Donepezil for Cognitive Impairment in Parkinson's Disease: A Randomised Controlled Study
JNNP 72:708-712, Aarsland,D.,et al, 2002
Efficacy of Galantamine in Probable Vascular Dementia and Alzheimer's Disease Combined with Cerebrovascular Disease: A Randomised Trial
Lancet 359:1283-1290,1265, Erkinjuntti,T.,et al, 2002
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
Metrifonate Benefits Cognitive, Behvioral, and Global Function in Patients with Alzheimer's Disease
Neurol 50:1222-1230, 12031998., Morris,J.C.,et al, 1998
Metrifonate Treatment of the Cognitive Deficits of Alzheimer's Disease
Neurol 50:1214-1221, 12031998., Cummings,J.L.,et al, 1998
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter 39:53-54, , 1997
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997
Clinical Experience with Donepezil Hydrochloride:A Case Study Perspective
Advan Therapy 14:305-311, Geldmacher,D.S., 1997
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA 268:2523-2529, 25641992., Farlow,M.,et al, 1992
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Dissease
NEJM 327:1253-1259, 13061992., Davis,K.L.,et al, 1992
Tacrine (tetrahydroaminoacridine; THA) and Lecithin in Senile Dememtia of the Alzheimer Type:A Multicentre Trial
BMJ 300:495-499, Chatellier,G.,et al, 1990
Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type
NEJM 315:1241-1245, Summers,W.K.,et al, 1986
Positive Response to Edrophonium in Patients with Neurotoxic Envenoming by Cobras (NAJA NAJA PHILIPPINENIS)
NEJM 315:1444-1448, Watt,G.,et al, 1986